<DOC>
	<DOC>NCT00235937</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and Zoladex® 3,6 Mg in injections under cutaneous once per month in subjects with breast cancer.</brief_summary>
	<brief_title>Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Signed informed consent, premenopausal women 18 years or older, histologically or cytologically confirmed locally advanced or metastatic breast cancer, suitable for endocrine treatment, no curative treatment available,, one or more measurable lesions, life expectancy more than 6 months, normal biological parameters. Presence of lifethreatening metastases, previous endocrine therapy or chemotherapy for advanced or metastatic disease, any previous treatment with hormone (LHRH) severe or uncontrolled systemic disease, pituitary adenoma, High risk of medullar compression.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Premenopausal</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>